Home > Cardiology > ESC 2021 > Polypill including aspirin most successful for preventing CVD events

Polypill including aspirin most successful for preventing CVD events

Presented By
Prof. Philip Joseph, McMaster University, Canada
ESC 2021
TIPS-3; HOPE-3; Polylran
A meta-analysis of 3 large primary prevention trials revealed that fixed-dose combination treatments are successful to prevent cardiovascular (CV) death, myocardial infarction (MI), stroke, or revascularisation. Benefits are most pronounced in the elderly. About 80% of cardiovascular disease (CVD) events occur in individuals without prior vascular disease. “Therefore, strategies that avoid a high proportion of first CVD events are critical to reducing global CVD burden,” said Prof. Philip Joseph (McMaster University; Hamilton Health Services, Canada) [1]. Fixed-dose combination (FDC) treatment could substantially reduce CVD risk, but more data are needed to quantify efficacy. The so-called polypill in a single formulation usually contains 2+ blood pressure-lowering agents, a statin, and eventually aspirin. In their meta-analysis of long-term, randomised controlled trials (each including >1,000 participants >2 years follow-up), the researchers tested ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on